Frontier Biotechnologies Inc. (SHA:688221)
8.52
-0.12 (-1.39%)
At close: Apr 25, 2025, 2:57 PM CST
Frontier Biotechnologies Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Cash & Equivalents | - | 526.66 | 550.89 | 800.85 | 839.09 | Upgrade
|
Trading Asset Securities | - | 415.06 | 690.11 | 679.36 | 939.58 | Upgrade
|
Cash & Short-Term Investments | 662.47 | 941.72 | 1,241 | 1,480 | 1,779 | Upgrade
|
Cash Growth | -29.65% | -24.12% | -16.16% | -16.78% | 332.03% | Upgrade
|
Accounts Receivable | - | 63.01 | 36.14 | 22.34 | 31.87 | Upgrade
|
Other Receivables | - | 2.37 | 10.55 | 1.13 | 1.1 | Upgrade
|
Receivables | - | 65.38 | 46.68 | 23.48 | 32.97 | Upgrade
|
Inventory | - | 59 | 55.61 | 38.62 | 13.53 | Upgrade
|
Other Current Assets | - | 36.68 | 62.78 | 35.2 | 23 | Upgrade
|
Total Current Assets | - | 1,103 | 1,406 | 1,578 | 1,848 | Upgrade
|
Property, Plant & Equipment | - | 793.02 | 728.06 | 605.76 | 239.22 | Upgrade
|
Other Intangible Assets | - | 229.18 | 257.22 | 258.44 | 289.49 | Upgrade
|
Long-Term Deferred Charges | - | 0.94 | 2.74 | 3.12 | 3.05 | Upgrade
|
Other Long-Term Assets | - | 14.21 | 16.76 | 87.8 | 136.36 | Upgrade
|
Total Assets | - | 2,140 | 2,411 | 2,533 | 2,516 | Upgrade
|
Accounts Payable | - | 1.13 | 2.69 | 3.32 | 2.1 | Upgrade
|
Accrued Expenses | - | 37.39 | 41.84 | 38.98 | 34.02 | Upgrade
|
Short-Term Debt | - | 202.3 | 110.64 | 52.19 | 14.99 | Upgrade
|
Current Portion of Long-Term Debt | - | 104.06 | 46 | 227.77 | 5 | Upgrade
|
Current Portion of Leases | - | 2.4 | 4.42 | 5.09 | - | Upgrade
|
Current Income Taxes Payable | - | - | - | - | 0.06 | Upgrade
|
Current Unearned Revenue | - | 5.83 | 0.06 | - | - | Upgrade
|
Other Current Liabilities | - | 27.04 | 71.58 | 72.14 | 56.55 | Upgrade
|
Total Current Liabilities | - | 380.16 | 277.23 | 399.49 | 112.71 | Upgrade
|
Long-Term Debt | - | 71.42 | 117.12 | 7.5 | 12.5 | Upgrade
|
Long-Term Leases | - | 0.17 | 0.45 | 0.41 | - | Upgrade
|
Long-Term Unearned Revenue | - | 329.35 | 323.54 | 269.41 | 250.46 | Upgrade
|
Other Long-Term Liabilities | - | 16.35 | 21.08 | 25.59 | - | Upgrade
|
Total Liabilities | - | 797.44 | 739.41 | 702.41 | 375.67 | Upgrade
|
Common Stock | - | 374.58 | 374.58 | 359.76 | 359.76 | Upgrade
|
Additional Paid-In Capital | - | 2,723 | 2,723 | 2,540 | 2,593 | Upgrade
|
Retained Earnings | - | -1,755 | -1,426 | -1,069 | -809.31 | Upgrade
|
Comprehensive Income & Other | - | 0.01 | 0.03 | -0.05 | -0.03 | Upgrade
|
Total Common Equity | 1,149 | 1,343 | 1,671 | 1,830 | 2,143 | Upgrade
|
Minority Interest | - | - | - | - | -2.42 | Upgrade
|
Shareholders' Equity | 1,149 | 1,343 | 1,671 | 1,830 | 2,141 | Upgrade
|
Total Liabilities & Equity | - | 2,140 | 2,411 | 2,533 | 2,516 | Upgrade
|
Total Debt | 448.63 | 380.35 | 278.62 | 292.96 | 32.49 | Upgrade
|
Net Cash (Debt) | 213.83 | 561.37 | 962.38 | 1,187 | 1,746 | Upgrade
|
Net Cash Growth | -61.91% | -41.67% | -18.94% | -32.01% | 369.77% | Upgrade
|
Net Cash Per Share | 0.57 | 1.50 | 2.64 | 3.29 | 6.05 | Upgrade
|
Filing Date Shares Outstanding | 374.58 | 374.58 | 374.58 | 359.76 | 359.76 | Upgrade
|
Total Common Shares Outstanding | 374.58 | 374.58 | 374.58 | 359.76 | 359.76 | Upgrade
|
Working Capital | - | 722.63 | 1,129 | 1,178 | 1,735 | Upgrade
|
Book Value Per Share | 3.07 | 3.58 | 4.46 | 5.09 | 5.96 | Upgrade
|
Tangible Book Value | 974.53 | 1,114 | 1,414 | 1,572 | 1,854 | Upgrade
|
Tangible Book Value Per Share | 2.60 | 2.97 | 3.78 | 4.37 | 5.15 | Upgrade
|
Buildings | - | 76.22 | 76.22 | - | - | Upgrade
|
Machinery | - | 47.35 | 45.92 | 30.44 | 35.06 | Upgrade
|
Construction In Progress | - | 695.97 | 622.9 | 582.29 | 220.54 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.